Transient tissue ‘priming’ via FAK inhibition to impair pancreatic cancer progression and improve sensitivity to gemcitabine/Abraxane

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1140125

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The success of cancer drugs is dependent on many factors including the properties of the tumour tissue. As a tumour grows it changes the tissue around it, and this affects response to treatment. Combining classical biology with engineering to generate 3D models that mimic tumours, along with cutting-edge imaging technology and mouse models, we will target FAK-controlled cancer cell pathways that sense tissue changes, together with already approved cancer drugs to improve patient outcome.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $643,848.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Cell Biology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biomechanics | cancer metastasis | extracellular matrix | pancreatic cancer | targeted therapy

Related Links